XML 34 R18.htm IDEA: XBRL DOCUMENT v3.10.0.1
BUSINESS CONCENTRATIONS
12 Months Ended
Dec. 31, 2018
Risks and Uncertainties [Abstract]  
BUSINESS CONCENTRATIONS

NOTE 12 - BUSINESS CONCENTRATIONS

 

We purchase our prescription products from several suppliers with approximately 43%, 33% and 24% of our purchases were supplied by three vendors each, respectively, during the year ended December 31, 2018, and 100% and 98% of our purchases were supplied by one vendor each for the years ended December 31, 2017 and 2016, respectively.

 

We sell our prescription products to wholesale distributors, specialty pharmacies, specialty distributors, and chain drug stores that generally sell products to retail pharmacies, hospitals, and other institutional customers. During the years ended December 31, 2018, 2017 and 2016, four, four and three customers each, respectively, accounted for more than 10% of our total net revenues. Net revenue from the four customers combined accounted for approximately 76% of our net recognized revenue for the year ended December 31, 2018 and approximately 59% of our recognized revenue for the year ended December 31, 2017. Net revenue from three customers combined accounted for approximately 41% of our net revenue during the year ended December 31, 2016.

 

During the year ended December 31, 2018, McKesson Corporation accounted for approximately $1,610,000 of our revenue, Pillpack, Inc. accounted for approximately $5,075,000 of our revenue, AmerisourceBergen accounted for approximately $3,246,000 of our revenue and Cardinal Health accounted for approximately $2,308,000 of our revenue. During the year ended December 31, 2017, AmerisourceBergen accounted for approximately $2,667,000 of our revenue; McKesson Corporation accounted for approximately $1,959,000 of our revenue; Cardinal Health accounted for approximately $2,559,000 of our revenue and Pharmacy Innovations PA accounted for approximately $2,715,000 of our revenue. During the year ended December 31, 2016, Woodstock Pharmaceutical and Compounding accounted for approximately $2,247,000 of our revenue; Medical Center Pharmacy accounted for approximately $3,700,000 of our revenue and Pharmacy Innovations PA accounted for approximately $2,040,000 of our revenue.